Matrix Metalloproteinase Inhibitors
"Matrix Metalloproteinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the enzyme activity or activation of MATRIX METALLOPROTEINASES.
| Descriptor ID |
D061965
|
| MeSH Number(s) |
D27.505.519.389.745.610
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Matrix Metalloproteinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Matrix Metalloproteinase Inhibitors".
This graph shows the total number of publications written about "Matrix Metalloproteinase Inhibitors" by people in this website by year, and whether "Matrix Metalloproteinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 2 | 3 | 5 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 4 | 5 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 3 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Matrix Metalloproteinase Inhibitors" by people in Profiles.
-
Susceptibility of Rat Steatotic Liver to Ischemia-Reperfusion Is Treatable With Liver-Selective Matrix Metalloproteinase Inhibition. Hepatology. 2020 11; 72(5):1771-1785.
-
Protective Effects of Activated Myofibroblasts in the Pressure-Overloaded Myocardium Are Mediated Through Smad-Dependent Activation of a Matrix-Preserving Program. Circ Res. 2019 04 12; 124(8):1214-1227.
-
MMP-8 Is Critical for Dexamethasone Therapy in Alkali-Burned Corneas Under Dry Eye Conditions. J Cell Physiol. 2016 11; 231(11):2506-16.
-
Hypothesis: Metalloproteinase Inhibitors Decrease Risks of Cardiovascular Disease. J Cardiovasc Pharmacol Ther. 2016 07; 21(4):368-71.
-
Mast cell-restricted, tetramer-forming tryptases induce aggrecanolysis in articular cartilage by activating matrix metalloproteinase-3 and -13 zymogens. J Immunol. 2013 Aug 01; 191(3):1404-12.
-
GnRH-(1-5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor. Mol Endocrinol. 2014 Jan; 28(1):80-98.
-
Anacardic acid inhibits the catalytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9. Mol Pharmacol. 2012 Oct; 82(4):614-22.
-
Potential contribution of hypoxia-inducible factor-1a, aquaporin-4, and matrix metalloproteinase-9 to blood-brain barrier disruption and brain edema after experimental subarachnoid hemorrhage. J Mol Neurosci. 2012 Sep; 48(1):273-80.
-
Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery. 2011 Apr; 149(4):504-11.
-
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res. 2010; 12(6):R96.